Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative.

Cuypers M, Al-Itejawi HHM, van Uden-Kraan CF, Stalmeier PFM, Lamers RED, van Oort IM, Somford DM, van Moorselaar RJA, Verdonck-de Leeuw IM, van de Poll-Franse LV, van Tol-Geerdink JJ, de Vries M.

J Cancer Educ. 2019 Jul 5. doi: 10.1007/s13187-019-01572-9. [Epub ahead of print]

PMID:
31278659
2.

Effectiveness of a web-based treatment decision aid for men with lower urinary tract symptoms due to benign prostatic hyperplasia.

van der Wijden FC, de Angst IB, Lamers RED, Cuypers M, de Vries M, van Melick HHE, de Beij JS, Oerlemans DJAJ, van de Beek K, Kil PJM.

BJU Int. 2019 Jul;124(1):124-133. doi: 10.1111/bju.14646. Epub 2019 Mar 4.

PMID:
30589205
3.

Longitudinal regret and information satisfaction after deciding on treatment for localized prostate cancer with or without a decision aid. Results at one-year follow-up in the PCPCC trial.

Cuypers M, Lamers RED, Kil PJM, van de Poll-Franse LV, de Vries M.

Patient Educ Couns. 2019 Mar;102(3):424-428. doi: 10.1016/j.pec.2018.10.006. Epub 2018 Oct 4.

PMID:
30314830
4.

Uptake and usage of an online prostate cancer treatment decision aid in Dutch clinical practice: A quantitative analysis from the Prostate Cancer Patient Centered Care trial.

Cuypers M, Lamers RE, Kil PJ, van Tol-Geerdink JJ, van Uden-Kraan CF, van de Poll-Franse LV, de Vries M.

Health Informatics J. 2019 Dec;25(4):1498-1510. doi: 10.1177/1460458218779110. Epub 2018 Jun 1.

PMID:
29857789
5.

Impact of a web-based prostate cancer treatment decision aid on patient-reported decision process parameters: results from the Prostate Cancer Patient Centered Care trial.

Cuypers M, Lamers RED, Kil PJM, van de Poll-Franse LV, de Vries M.

Support Care Cancer. 2018 Nov;26(11):3739-3748. doi: 10.1007/s00520-018-4236-8. Epub 2018 May 12.

6.

The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset.

Cuypers M, Lamers RED, Cornel EB, van de Poll-Franse LV, de Vries M, Kil PJM.

Support Care Cancer. 2018 Apr;26(4):1297-1304. doi: 10.1007/s00520-017-3953-8. Epub 2017 Nov 10.

7.

A global, incremental development method for a web-based prostate cancer treatment decision aid and usability testing in a Dutch clinical setting.

Cuypers M, Lamers RE, Kil PJ, The R, Karssen K, van de Poll-Franse LV, de Vries M.

Health Informatics J. 2019 Sep;25(3):701-714. doi: 10.1177/1460458217720393. Epub 2017 Jul 27.

PMID:
28747076
8.

How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer.

Lamers RE, Cuypers M, de Vries M, van de Poll-Franse LV, Ruud Bosch JL, Kil PJ.

Urol Oncol. 2017 Feb;35(2):37.e9-37.e17. doi: 10.1016/j.urolonc.2016.09.007. Epub 2016 Oct 27.

PMID:
28341494
9.

The Type IVa Pilus Machinery Is Recruited to Sites of Future Cell Division.

Carter T, Buensuceso RN, Tammam S, Lamers RP, Harvey H, Howell PL, Burrows LL.

MBio. 2017 Jan 31;8(1). pii: e02103-16. doi: 10.1128/mBio.02103-16.

10.

Structure of the Pseudomonas aeruginosa Type IVa Pilus Secretin at 7.4 Å.

Koo J, Lamers RP, Rubinstein JL, Burrows LL, Howell PL.

Structure. 2016 Oct 4;24(10):1778-1787. doi: 10.1016/j.str.2016.08.007.

11.

Prostate cancer survivors with a passive role preference in treatment decision-making are less satisfied with information received: Results from the PROFILES registry.

Cuypers M, Lamers RED, de Vries M, Husson O, Kil PJM, van de Poll-Franse LV.

Urol Oncol. 2016 Nov;34(11):482.e11-482.e18. doi: 10.1016/j.urolonc.2016.06.015. Epub 2016 Jul 16.

PMID:
27432432
12.

Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.

Lamers RP, Burrows LL.

Future Med Chem. 2016 Jun;8(9):975-92. doi: 10.4155/fmc-2016-0017. Epub 2016 May 26. Review.

PMID:
27228070
13.

Development of a decision aid for the treatment of benign prostatic hyperplasia: A four stage method using a Delphi consensus study.

Lamers RED, Cuypers M, Garvelink MM, de Vries M, Bosch JLHR, Kil PJM.

Patient Educ Couns. 2016 Jul;99(7):1249-1256. doi: 10.1016/j.pec.2016.02.004. Epub 2016 Feb 8.

PMID:
26899631
14.

Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients.

Lamers RE, Cuypers M, Husson O, de Vries M, Kil PJ, Ruud Bosch JL, van de Poll-Franse LV.

Psychooncology. 2016 Jun;25(6):633-40. doi: 10.1002/pon.3981. Epub 2015 Sep 25.

PMID:
26403417
15.

Loss of membrane-bound lytic transglycosylases increases outer membrane permeability and β-lactam sensitivity in Pseudomonas aeruginosa.

Lamers RP, Nguyen UT, Nguyen Y, Buensuceso RN, Burrows LL.

Microbiologyopen. 2015 Dec;4(6):879-95. doi: 10.1002/mbo3.286. Epub 2015 Sep 15.

16.

Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial.

Cuypers M, Lamers RE, Kil PJ, van de Poll-Franse LV, de Vries M.

Trials. 2015 May 27;16:231. doi: 10.1186/s13063-015-0750-x.

17.

Chronic alcohol consumption promotes alterations on salivary gland regeneration process.

Nör F, Hartmann MD, Slongo PR, Lamers RL, Fossati AC.

Microsc Res Tech. 2013 Nov;76(11):1125-30. doi: 10.1002/jemt.22275. Epub 2013 Aug 7.

PMID:
23922216
18.

Longitudinal genetic analyses of Staphylococcus aureus nasal carriage dynamics in a diverse population.

Muthukrishnan G, Lamers RP, Ellis A, Paramanandam V, Persaud AB, Tafur S, Parkinson CL, Cole AM.

BMC Infect Dis. 2013 May 16;13:221. doi: 10.1186/1471-2334-13-221.

19.

Changes to its peptidoglycan-remodeling enzyme repertoire modulate β-lactam resistance in Pseudomonas aeruginosa.

Cavallari JF, Lamers RP, Scheurwater EM, Matos AL, Burrows LL.

Antimicrob Agents Chemother. 2013 Jul;57(7):3078-84. doi: 10.1128/AAC.00268-13. Epub 2013 Apr 22.

20.

The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria.

Lamers RP, Cavallari JF, Burrows LL.

PLoS One. 2013;8(3):e60666. doi: 10.1371/journal.pone.0060666. Epub 2013 Mar 27.

21.

Iodine-129 microdosing for protein and peptide drug development: erythropoietin as a case study.

Lamers RJ, de Jong AF, López-Gutiérrez JM, Gómez-Guzmán J.

Bioanalysis. 2013 Jan;5(1):53-63. doi: 10.4155/bio.12.297.

PMID:
23256472
22.

Phylogenetic relationships among Staphylococcus species and refinement of cluster groups based on multilocus data.

Lamers RP, Muthukrishnan G, Castoe TA, Tafur S, Cole AM, Parkinson CL.

BMC Evol Biol. 2012 Sep 6;12:171. doi: 10.1186/1471-2148-12-171.

23.

Characterization of the retrocyclin analogue RC-101 as a preventative of Staphylococcus aureus nasal colonization.

Lamers RP, Eade CR, Waring AJ, Cole AL, Cole AM.

Antimicrob Agents Chemother. 2011 Nov;55(11):5338-46. doi: 10.1128/AAC.00619-11. Epub 2011 Aug 8.

24.

Exoproteome of Staphylococcus aureus reveals putative determinants of nasal carriage.

Muthukrishnan G, Quinn GA, Lamers RP, Diaz C, Cole AL, Chen S, Cole AM.

J Proteome Res. 2011 Apr 1;10(4):2064-78. doi: 10.1021/pr200029r. Epub 2011 Mar 7.

25.

Evolutionary analyses of Staphylococcus aureus identify genetic relationships between nasal carriage and clinical isolates.

Lamers RP, Stinnett JW, Muthukrishnan G, Parkinson CL, Cole AM.

PLoS One. 2011 Jan 21;6(1):e16426. doi: 10.1371/journal.pone.0016426.

26.

A search for biomarkers as diagnostic tools for food allergy: a pilot study in peanut-allergic patients.

Peeters KA, Lamers RJ, Penninks AH, Knol EF, Bruijnzeel-Koomen CA, van Nesselrooij JH, Knulst AC.

Int Arch Allergy Immunol. 2011;155(1):23-30. doi: 10.1159/000318654. Epub 2010 Nov 25.

PMID:
21109745
27.

Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins.

Stoop MP, Dekker LJ, Titulaer MK, Lamers RJ, Burgers PC, Sillevis Smitt PA, van Gool AJ, Luider TM, Hintzen RQ.

J Proteome Res. 2009 Mar;8(3):1404-14. doi: 10.1021/pr8010155.

PMID:
19159215
28.

Postmortem miscoding lesions in sequence analysis of human ancient mitochondrial DNA.

Lamers R, Hayter S, Matheson CD.

J Mol Evol. 2009 Jan;68(1):40-55. doi: 10.1007/s00239-008-9184-3. Epub 2008 Dec 6.

PMID:
19067027
29.

The rate of false positive sequence matches of peptides profiled by MALDI MS and identified by MS/MS.

Stoop MP, Lamers RJ, Burgers PC, Sillevis Smitt PA, Hintzen RQ, Luider TM.

J Proteome Res. 2008 Nov;7(11):4841-7. doi: 10.1021/pr800489a. Epub 2008 Oct 7.

PMID:
18837534
30.

Regulation of the IgE response at the molecular level: impact on the development of systemic anti IgE therapeutic strategies.

Achatz G, Achatz-Straussberger G, Luger E, Lamers R, Crameri R.

Chem Immunol Allergy. 2006;91:204-17. Review.

PMID:
16354961
31.

Tracheal nodularity due to tracheobronchopathia osteochondroplastica.

De Bruin HG, Lamers RJ.

JBR-BTR. 2005 May-Jun;88(3):120-1. No abstract available.

PMID:
16038222
32.

Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis.

Heijne WH, Lamers RJ, van Bladeren PJ, Groten JP, van Nesselrooij JH, van Ommen B.

Toxicol Pathol. 2005;33(4):425-33.

PMID:
16036859
33.

Molecular and cellular targets of anti-IgE antibodies.

Inführ D, Crameri R, Lamers R, Achatz G.

Allergy. 2005 Aug;60(8):977-85. Review.

PMID:
15969677
34.

Identification of an urinary metabolite profile associated with osteoarthritis.

Lamers RJ, van Nesselrooij JH, Kraus VB, Jordan JM, Renner JB, Dragomir AD, Luta G, van der Greef J, DeGroot J.

Osteoarthritis Cartilage. 2005 Sep;13(9):762-8.

35.

Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology.

Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, van der Heijden R, Voshol PJ, Havekes LM, Verpoorte R, van der Greef J.

Phytother Res. 2005 Mar;19(3):173-82. Review.

PMID:
15934013
36.

ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data.

Smilde AK, Jansen JJ, Hoefsloot HC, Lamers RJ, van der Greef J, Timmerman ME.

Bioinformatics. 2005 Jul 1;21(13):3043-8. Epub 2005 May 12. Erratum in: Bioinformatics. 2007 Dec 15;23(24):3415.

PMID:
15890747
37.

Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data.

de Roos B, Duivenvoorden I, Rucklidge G, Reid M, Ross K, Lamers RJ, Voshol PJ, Havekes LM, Teusink B.

FASEB J. 2005 May;19(7):813-5. Epub 2005 Mar 8.

PMID:
15755870
38.

Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.

van Der Wel A, Nijsten S, Hochstenbag M, Lamers R, Boersma L, Wanders R, Lutgens L, Zimny M, Bentzen SM, Wouters B, Lambin P, De Ruysscher D.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):649-55.

PMID:
15708242
39.

Evidence of the regulatory effect of Ginkgo biloba extract on skin blood flow and study of its effects on urinary metabolites in healthy humans.

Boelsma E, Lamers RJ, Hendriks HF, van Nesselrooij JH, Roza L.

Planta Med. 2004 Nov;70(11):1052-7.

PMID:
15549661
40.

A pilot study to investigate effects of inulin on Caco-2 cells through in vitro metabolic fingerprinting.

Lamers RJ, Wessels EC, van de Sandt JJ, Venema K, Schaafsma G, van der Greef J, van Nesselrooij JH.

J Nutr. 2003 Oct;133(10):3080-4.

PMID:
14519788
41.

Sarcoidosis: assessment of disease severity using HRCT.

Drent M, De Vries J, Lenters M, Lamers RJ, Rothkranz-Kos S, Wouters EF, van Dieijen-Visser MP, Verschakelen JA.

Eur Radiol. 2003 Nov;13(11):2462-71. Epub 2003 Jun 17.

PMID:
12811502
42.

Identification of disease- and nutrient-related metabolic fingerprints in osteoarthritic Guinea pigs.

Lamers RJ, DeGroot J, Spies-Faber EJ, Jellema RH, Kraus VB, Verzijl N, TeKoppele JM, Spijksma GK, Vogels JT, van der Greef J, van Nesselrooij JH.

J Nutr. 2003 Jun;133(6):1776-80.

PMID:
12771316
43.

Mediastinal staging of lung cancer with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography and a dual-head coincidence gamma camera.

Zimny M, Hochstenbag M, Lamers R, Reinartz P, Cremerius U, ten Velde G, Buell U.

Eur Radiol. 2003 Apr;13(4):740-7. Epub 2002 Sep 7.

PMID:
12664112
44.
45.

Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer.

Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Lamers RJ, Slotman BJ, Wouters EF.

J Clin Oncol. 2001 Apr 15;19(8):2123-33.

PMID:
11304764
46.

External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study.

Langendijk H, de Jong J, Tjwa M, Muller M, ten Velde G, Aaronson N, Lamers R, Slotman B, Wouters M.

Radiother Oncol. 2001 Mar;58(3):257-68.

PMID:
11230886
47.

Necrotizing sarcoid granulomatosis.

Laurens DR, Lamers RJ.

JBR-BTR. 1999 Jun;82(3):114. No abstract available.

PMID:
11155871
48.

Association of man-made mineral fibre exposure and sarcoidlike granulomas.

Drent M, Bomans PH, Van Suylen RJ, Lamers RJ, Bast A, Wouters EF.

Respir Med. 2000 Aug;94(8):815-20.

49.

Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy.

Langendijk H, Thunnissen E, Arends JW, de Jong J, ten Velde G, Lamers R, Guinee D, Holden J, Wouters M.

Radiother Oncol. 2000 Aug;56(2):197-207.

PMID:
10927139
50.

Pitfall of the accessory spleen.

Sels JP, Wouters RM, Lamers R, Wolffenbuttel BH.

Neth J Med. 2000 Apr;56(4):153-8.

PMID:
10727761

Supplemental Content

Loading ...
Support Center